-
Thematic Analysis
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CV-301 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CV-301 in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CV-301 in Metastatic Colorectal Cancer Drug Details: CV-301 (PANVAC-VF) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-08046050 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-08046050 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-08046050 in Gastric Cancer Drug Details: PF-08046050 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-08046050 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-08046050 in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-08046050 in Small-Cell Lung Cancer Drug Details: PF-08046050 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-08046050 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-08046050 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-08046050 in Non-Small Cell Lung Cancer Drug Details: PF-08046050...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PF-08046050 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PF-08046050 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PF-08046050 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VG-201 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VG-201 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VG-201 in Ovarian Cancer Drug Details: VG-201 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VG-201 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VG-201 in Colon Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VG-201 in Colon Cancer Drug Details: VG-201 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VG-201 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VG-201 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VG-201 in Pancreatic Cancer Drug Details: VG-201 is under development for...